What’s at stake: Callaghan Innovation business unit GlycoSyn has worked with more than 100 drug companies worldwide to develop ingredients that are the key constituents of vaccines, antivirals, and rare disease therapies.
Background: GlycoSyn was born in 2003 out of the former IRL’s Carbohydrate Chemistry Team led by Professors Richard Furneaux and Peter Tyler – who later shifted to the Ferrier Institute.
Main players: GlycoSyn, Callaghan Innovation, the Ferrier Institute at Victoria University.
Molybdenum Cofactor Deficiency (MoCD) is a rare, genetic metabolic disorder that typically presents in the first few days of someone’s life. It causes seizures, brain injury, and death.
MoCD patients can’t produce a substance known as cyclic pyrantoperin monophosphate. In 2010, New Zealand
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
What’s at stake: Callaghan Innovation business unit GlycoSyn has worked with more than 100 drug companies worldwide to develop ingredients that are the key constituents of vaccines, antivirals, and rare disease therapies.
Background: GlycoSyn was born in 2003 out of the former IRL’s Carbohydrate Chemistry Team led by Professors Richard Furneaux and Peter Tyler – who later shifted to the Ferrier Institute.
Main players: GlycoSyn, Callaghan Innovation, the Ferrier Institute at Victoria University.